<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692324</url>
  </required_header>
  <id_info>
    <org_study_id>20-008832</org_study_id>
    <secondary_id>NCI-2021-02765</secondary_id>
    <secondary_id>20-008832</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04692324</nct_id>
  </id_info>
  <brief_title>Cerebrospinal Fluid Biomarkers for Brain Tumors</brief_title>
  <official_title>Cerebrospinal Fluid Biomarkers for Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines cerebrospinal biomarkers in patients with brain tumors. A biomarker is a&#xD;
      measurable indicator of the severity or presence of your disease state. Collecting and&#xD;
      storing samples of cerebrospinal fluid from patients with brain tumors to study in the&#xD;
      laboratory may help doctors develop new strategies to better diagnose, monitor, and treat&#xD;
      brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To collect cerebrospinal fluid (CSF) samples that can provide a resource to the research&#xD;
      community for biomarker discovery in patients with gliomas.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. Evaluate the feasibility of serial CSF sampling from patients with brain tumors for&#xD;
      longitudinal evaluation of tumor biomarkers.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo collection of CSF samples via lumbar puncture at least 2 times. Patients may&#xD;
      undergo additional collection of additional CSF samples if they choose.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collection cerebrospinal fluid (CSF) samples that can provide a resource to the research community for biomarker discovery</measure>
    <time_frame>Up to study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of serial cerebrospinal fluid (CSF) sampling</measure>
    <time_frame>Up to study completion</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Central Nervous System Neoplasm</condition>
  <arm_group>
    <arm_group_label>Basic science (biospecimen collection)</arm_group_label>
    <description>Patients undergo collection of CSF samples via lumbar puncture at least 2 times. Patients may undergo additional collection of additional CSF samples if they choose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of CSF samples</description>
    <arm_group_label>Basic science (biospecimen collection)</arm_group_label>
    <other_name>Biological Sample Collection</other_name>
    <other_name>Biospecimen Collected</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Review of medical records</description>
    <arm_group_label>Basic science (biospecimen collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Basic science (biospecimen collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cerebrospinal fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with central nervous system neoplasm&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent&#xD;
             structures in contact with CSF. Such lesions may include but are not limited to&#xD;
             intra-axial or extra-axial lesions, which could be benign, malignant or as yet&#xD;
             undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting&#xD;
             structures&#xD;
&#xD;
          -  Subjects must be 18 years of age or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are under 18 years of age or are a members of a vulnerable population&#xD;
             will be excluded from this study&#xD;
&#xD;
          -  Pregnant women or women who may be pregnant are specifically excluded from study&#xD;
             participation&#xD;
&#xD;
          -  Exception will be granted for patients with diminished capacity to consent if a&#xD;
             legally authorized representative is available&#xD;
&#xD;
          -  Patients without clinical or radiographic evidence of a potentially neoplastic CNS&#xD;
             lesion will be excluded&#xD;
&#xD;
          -  Patients with an inability or unwillingness of individual or legal&#xD;
             guardian/representative to give written informed consent will be excluded&#xD;
&#xD;
          -  Any patient for whom a clinical contraindication exists to the intended route of CSF&#xD;
             access will be excluded. For example, a patient with a large posterior fossa mass&#xD;
             lesion at risk of herniation, or a patient with coagulopathy, or other&#xD;
             contraindication to lumbar puncture would not be eligible to participate via use of&#xD;
             lumbar puncture for CSF access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence C Burns</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Terence C. Burns, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

